April 2014

Annual report SFI-CAST 2013


The Annual report for 2013 is now published

Annual Report 2013 



First Industry-Industry collaboration in SFI-CAST result in joint publication


The novel EpCAM-targeting monoclonal antibody 3–17I linked to saporin is highly cytotoxic after photochemical internalization in breast, pancreas and colon cancer cell lines

Link to the article published in mAbs



Dagens Medisin: Helseprioriteringene blir enda mer krevende


Dagens Medisin 3.Desember: Helseprioriteringene blir enda mer krevende

Leder for Norsk Kreftgenomikkonsortium, Ola Myklebost, (nestleder av SFI-CAST) fant nylig en bestemt mutasjon hos lungekreftpasienter som det var mulig å gi leukemi-legemidler mot. 



SFI-CAST workshop 22nd of November



09.00 - 15.30


8. nov. 2013

Dissertation and trial lecture: Jo Waaler - Kreftbehandling og kreftbiologi


Trial lecture

GSK3β as an integrator of multiple signaling pathways during normal development and cancer

8th of November 09.15, Seminarrom 1 B2.U001, Oslo universitetssykehus HF, Rikshospitalet


M.Sc. Jo Waaler: Development of specific tankyrase inhibitors for attenuating canonical Wnt/β-catenin signaling.

8th of November 11.15, Seminarrom 1 B2.U001, Oslo universitetssykehus HF, Rikshospitalet


14-15 October 2013

The 10th Annual Norwegian Stem Cell Networking Meeting, Oslo


The 10th Annual Norwegian Stem Cell Networking Meeting will be held on October 14-15

For more information visit NCS


August 2013

Gunhild Mælandsmo's latest paper to be published in BJC


In this prospective study, covered in "Clinical significance of disseminated tumour cells in non-small cell lung cancer", Mælandsmo et al. have investigated the presence of DTCs in the bone marrow collected from 296 patients with stages I–IIIA NSCLC undergoing curatively intended surgery, using both IMS and ICC. In addition, 81 bone marrow samples from healthy volunteers were investigated using IMS.

They have compared the results from the two methods, investigated the associations with clinicopathological parameters and examined the prognostic impact of the presence of DTCs.

This paper has been pre-published in the British Journal of Cancer's advanced online publication 13th of August 2013. 


14th - 16th July, 2013

Wnt Symposium 2013, Heidelberg


June 2013

Leonardo A. Meza-Zepeda head of project group "Translational Genomics"


Senior Scientist Leonardo A. Meza-Zepeda from Ola Myklebost's group "Molecular characterization of mesenchymal cancer" has become head of his own research group called "Translational Genomics". This research group is divided into to focus areas; Genetic and epigenetic networks of mesenchymal stem cell differentiation and Integrated analysis of genetic and epigenetic changes of human sarcomas.

By identifying and characterising the specific transcriptional programs active during differentiation of mesenchymal stem cells "Genetic and epigenetic networks of mesenchymal stem cell differentiation" work towards a better understanding of the blance between stemness and differentiation and its deregulation in cancer.

Integrated analysis of genetic and epigenetic changes of human sarcomas togheter with different EuroBoNet (European Network of Excellence for Bone Tumours) preclinical osteosarcoma panels (cell lines and xenografts) focus on unveiling pathways and transcriptional and gene networks in osteosarcomas (bone tumours) and the way these are controlled.
The analysis of Leonardo A. Meza-Zepeda's group has already identified the importance of epigenetic silencing in controlling gene expression.

For more information see the homepage for "Translational Genomics"


May 2013

Dr. Rolf Skotheim publishes in Nature Genetics


A new study looking at the genomes of more than 13,000 men identified four new genetic variants associated with an increased risk of testicular cancer, the most commonly diagnosed type in young men today. The findings from this first-of-its-kind meta-analysis were reported online May 12 in Nature Genetics by researchers in Norway and the United States.

This discovery could ultimately help researchers better understand which men are at high risk for for texticular cancer and allow for early detection or prevention of the disease.

“As we continue to cast a wider net, we identify additional genetic risk factors, which point to new mechanisms for disease,” said Katherine L. Nathanson, MD, associate professor in the division of Translational  Medicine and Human Genetics within the department of Medicine at the University of Pennsylvania. “Certain chromosomal regions, what we call loci, are tied into testicular cancer susceptibility, and represent a promising path to stratifying patients into risk groups—for a disease we know is highly heritable.” - writes Penn Medicine

Despite being a heritable disease, testicular cancer is actually relatively rare. The incidence rates have however doubled in the past 40 years.


May 2013 (Norwegian only)

Forskere hos PCI Biotech imponerer

Monica Bostad og Pål Selbo.
Bilde tatt av Arnfinn Christensen
Monica Bostad og Pål Selbo. Bilde tatt av Arnfinn Christensen

PCI's banebrytende forskning på fotokjemisk internalisering har vakt oppsikt i nasjonal media.

"PCI-metoden (photochemical internalization)  ble oppfunnet i 1995 av den norske forskeren Kristian Berg.
Kristian Berg er i dag professor ved Seksjon for strålingsbiologi, Institutt for kreftforskning på Senter for forskningsdrevet innovasjon. Pål Selbo og Monica Bostad arbeider i hans forskningsgruppe.

Metoden og det fotosensibiliserende stoffet Amphinex kan også brukes i andre sammenhenger enn beskrevet i denne artikkelen.
Blant annet har forskergruppen vist med museforsøk at PCI kan frigjøre et antibiotikum, bleomycin, som også bekjemper kreftceller.

Denne metoden er nå under utprøving i et Fase II-studium på fem anerkjente kreftsykehus i Europa.

Forskningen som er beskrevet i artikkelen, er finansiert av Norges Forskningsråd, Radiumhospitalets Forskningsstiftelse og Kreftforeningen

Se fullstendig artikkel på     


April 2013

Excellent Researcher Award to Dr. Harald Stenmark


Nine research awards were distributed to scientists from Oslo University Hospital on Friday, April 26th. The prizes were given out by Bjørn Erikstein, managing director at the hospital during a ceremony taking place at Rikshospitalet, Gaustad.

Dr. Harald Stenmark was the first ever to recieve the "Excellent Researcher Award". The award prize is a total of 300 000 NOK.

Also two "Early Career Awards" were presented, each amounting to 150 000 NOK. Guro Elisabeth Lind and Tom Hemming Karlsen received these prizes.

In addition six excellent research articles were awarded 50 000 NOK each.

For more information see Oslo University Hospital webpage or  


April 2013

As a proof-of-concept, Bostad et al., demonstrate for the first time that PCI can be used to deliver therapeutics that target cancer stem cells (CSCs)

Monica Bostad og Pål Selbo
Monica Bostad og Pål Selbo

The manuscript first-authored by Monica Bostad from Kristian Berg's group at the Department of Radiation Biology - entitled “Photochemical internalization (PCI) of immunotoxins targeting CD133 is specific and highly potent at femtomolar levels in cells with cancer stem cell properties” was recently published in the highly recognized drug delivery periodical "Journal of Controlled Release" (5 year impact factor: 7.529, NIFU step level 2).

As a proof-of-concept, Bostad et al., demonstrate for the first time that PCI can be used to deliver therapeutics that target cancer stem cells (CSCs).



Available Positions


There are no available positions at the moment.